BMC Neurology
(Mar 2020)
Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
- Mark E. Bangs,
- David Kudrow,
- Shufang Wang,
- Tina M. Oakes,
- Gisela M. Terwindt,
- Delphine Magis,
- Laura Yunes-Medina,
- Virginia L. Stauffer
Affiliations
- Mark E. Bangs
- Eli Lilly and Company
- David Kudrow
- California Medical Clinic for Headache
- Shufang Wang
- Eli Lilly and Company
- Tina M. Oakes
- Eli Lilly and Company
- Gisela M. Terwindt
- Leiden University Medical Center
- Delphine Magis
- Neurology Dept and Pain Clinic (CMTD), CHR East Belgium
- Laura Yunes-Medina
- Eli Lilly and Company
- Virginia L. Stauffer
- Eli Lilly and Company
- DOI
-
https://doi.org/10.1186/s12883-020-01675-7
- Journal volume & issue
-
Vol. 20,
no. 1
pp.
1
– 2
Abstract
Read online
Following publication of the original article [1], the authors noticed an error in the values for ‘Hypersensitivity SMQ’ and ‘Rash’ in Table 7.
WeChat QR code
